Molecular biomarkers of blunt cardiac injury: recent advances and future perspectives.

IF 3.9 3区医学 Q1 PATHOLOGY

Expert Review of Molecular Diagnostics Pub Date : 2024-11-01 Epub Date: 2024-09-20 DOI:10.1080/14737159.2024.2405919

Ning Wang, Jiliang Huang, Ying Fang, Honglin Du, Yanlin Chen, Shuquan Zhao

{"title":"Molecular biomarkers of blunt cardiac injury: recent advances and future perspectives.","authors":"Ning Wang, Jiliang Huang, Ying Fang, Honglin Du, Yanlin Chen, Shuquan Zhao","doi":"10.1080/14737159.2024.2405919","DOIUrl":null,"url":null,"abstract":"Introduction: Blunt cardiac injury (BCI), associated with high morbidity and mortality, involves multiple injuries. With no widely accepted gold standard diagnostic test and molecular biomarkers still in debate and far from application in clinical practice, exploring specific molecular biomarkers of BCI is of great significance. The clarification of molecular biomarkers can improve the diagnosis of BCI, leading to more precise care for victims in various situations.Areas covered: Using the search term 'Biomarker AND Blunt cardiac injury,' we carefully reviewed related papers from June 2004 to June 2024 in PubMed and CNKI. After reviewing, we included 20 papers, summarizing the biomarkers reported in previous studies, and then reviewed molecular biomarkers such as troponins, Nterminal proBtype natriuretic peptide (NT proBNP), hearttype fatty acid binding protein (hFABP), and lactate for BCI diagnosis. Finally, valuable views on future research directions for diagnostic biomarkers of BCI were presented.Expert opinion: Several advanced technologies have been introduced into clinical medicine, which have ultimately changed the research on cardiac diseases in recent years. Some biomarkers have been identified and utilized for BCI diagnosis. Herein, we summarize the latest relevant information as a reference for clinical practice and future studies.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1023-1031"},"PeriodicalIF":3.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2024.2405919","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Blunt cardiac injury (BCI), associated with high morbidity and mortality, involves multiple injuries. With no widely accepted gold standard diagnostic test and molecular biomarkers still in debate and far from application in clinical practice, exploring specific molecular biomarkers of BCI is of great significance. The clarification of molecular biomarkers can improve the diagnosis of BCI, leading to more precise care for victims in various situations.

Areas covered: Using the search term 'Biomarker AND Blunt cardiac injury,' we carefully reviewed related papers from June 2004 to June 2024 in PubMed and CNKI. After reviewing, we included 20 papers, summarizing the biomarkers reported in previous studies, and then reviewed molecular biomarkers such as troponins, Nterminal proBtype natriuretic peptide (NT proBNP), hearttype fatty acid binding protein (hFABP), and lactate for BCI diagnosis. Finally, valuable views on future research directions for diagnostic biomarkers of BCI were presented.

Expert opinion: Several advanced technologies have been introduced into clinical medicine, which have ultimately changed the research on cardiac diseases in recent years. Some biomarkers have been identified and utilized for BCI diagnosis. Herein, we summarize the latest relevant information as a reference for clinical practice and future studies.

查看原文本刊更多论文

钝性心脏损伤的分子生物标记物：最新进展与未来展望。

导言：钝性心脏损伤（BCI）与高发病率和高死亡率相关，涉及多种损伤。由于目前尚无广泛接受的金标准诊断测试，分子生物标志物仍在争论中，远未应用于临床实践，因此探索钝性心脏损伤的特异性分子生物标志物意义重大。明确分子生物标志物可以改善脑损伤的诊断，从而为各种情况下的受害者提供更精确的治疗：以 "生物标志物 AND 钝性心脏损伤 "为检索词，我们仔细查阅了 PubMed 和 CNKI 中 2004 年 6 月至 2024 年 6 月的相关论文。经过检索，我们收录了 20 篇论文，总结了以往研究中报道的生物标志物，然后回顾了用于 BCI 诊断的肌钙蛋白、Nterminal proB 型钠尿肽（NT proBNP）、心型脂肪酸结合蛋白（hFABP）和乳酸盐等分子生物标志物。最后，就 BCI 诊断生物标志物的未来研究方向提出了宝贵意见：近年来，一些先进技术被引入临床医学，最终改变了心脏疾病的研究。一些生物标志物已被确定并用于心搏过速的诊断。在此，我们总结了最新的相关信息，为临床实践和未来研究提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Molecular Diagnostics 医学-病理学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy. Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.